Toggle Nav

Topotecan HCl

In stock
Catalog No.
B2296
Topoisomerase 1 inhibitor
Grouped product items
SizePriceStock Qty
10mM (in 1mL DMSO)
$55.00
In stock
10mg
$40.00
In stock
50mg
$130.00
In stock
100mg
$150.00
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

Topotecan HCl(SKF104864)is an inhibitor of topoisomerase 1 and semisynthetic analogue of camptothecin [1].

Topotecan HCl(SKF104864)has been reported to have a potent antitumor activity against tumors in murine models. In addition, Topotecan HCl has also shown the potent effect against intravenously implanted P388 leukemia and both intravenously and subcutaneously implanted Lewis lung carcinoma. Topotecan HCl has noted the activity against subcutaneously implanted solid tumors including chemorefractory tumors and human colon carcinoma xenograft HT-29. Topotecan HCl has been found to induce regressions in the lung tumor model (Lewis lung carcinoma and B16 melanoma), compared to camptothecin and 9-amino-camptothecin. In the preclinical toxicology studies, Topotecan HCl has been revealed to have a concentration-dependent, reversible and limited toxoicity to rapidly proliferation tissues such as bone marrow and gastro-intestinal epithelium [1].

References:
[1] Creemers GJ1, Lund B, Verweij J. Topoisomerase I inhibitors: topotecan and irenotecan. Cancer Treat Rev. 1994 Jan;20(1):73-96.

Chemical Properties

Physical AppearanceA solid
StorageStore at -20°C
M.Wt457.91
Cas No.119413-54-6
FormulaC23H24ClN3O5
Solubility≥22.9mg/mL in DMSO
Chemical Name(S)-10-((dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione hydrochloride
SDFDownload SDF
Canonical SMILESCl[H].O=C1N(C([H])([H])C2=C([H])C(C(C([H])([H])N(C([H])([H])[H])C([H])([H])[H])=C3O[H])=C(C([H])=C3[H])N=C42)C4=C([H])C([[email protected]@](C([H])([H])C([H])([H])[H])5O[H])=C1C([H])([H])OC5=O
Shipping ConditionEvaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.

Protocol

Cell experiment:

Cell lines

MCF-7 breast cancer cell line, human prostate cancer cell lines (PC-3 and LNCaP)

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

500 nM for 6-12 days; or 2, 10 nM for 72 h

Applications

Topotecan-treated cells showed an impaired sphere-forming capacity in vitro. Topotecan-induced ABCG2 expression in MCF-7 cells was associated with decreased CD24/EpCAM expression [1]. Moreover, Topotecan treatment concentration-dependently increased the cytotoxicity in PC-3 and LNCaP cells [2].

Animal experiment:

Animal models

Newborn NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice or adult NMRI-nu/nu mice model; PC-3 xenograft model

Dosage form

2.45 and 0.10 mg/kg/day; intra-tumor injections, continuous infusion or conventional I.V., for 30 days;

Applications

Topotecan-treated cells decreased tumorigenicity in immunodeficient mice [1]. Moreover, low-dose continuous administration of topotecan enhanced antitumor activity in prostate cancer [2].

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

1. Huber, S., Wege, A. K., Bernhardt, G., Buschauer, A. and Brockhoff, G. (2015) Topotecan-induced ABCG2 expression in MCF-7 cells is associated with decreased CD24 and EpCAM expression and a loss of tumorigenicity. Cytometry A. 87, 707-716

2. Aljuffali, I. A., Mock, J. N., Costyn, L. J., Nguyen, H., Nagy, T., Cummings, B. S. and Arnold, R. D. (2011) Enhanced antitumor activity of low-dose continuous administration schedules of topotecan in prostate cancer. Cancer Biol Ther. 12, 407-420

Quality Control